WDB002 / Revolution Medicines 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  sirolimus / Generic mfg.
    Journal:  Genomic discovery of an evolutionarily programmed modality for small-molecule targeting of an intractable protein surface. (Pubmed Central) -  Aug 18, 2020   
    The flat-targeting modality demonstrated here has the potential to expand the druggable target range of small-molecule therapeutics. As CEP250 was recently found to be an interaction partner with the Nsp13 protein of the SARS-CoV-2 virus that causes COVID-19 disease, it is possible that WDB002 or an analog may exert useful antiviral activity through its ability to form high-affinity ternary complexes containing CEP250 and FKBP12.